Global Apixaban Market Overview
Apixaban is an anticoagulant licenced by the Food and Drug Administration (FDA) for the treatment of venous thromboembolic events (blood clots) that occur within a vein. It is used as a replacement for warfarin, and it does not require blood testing or dietary restrictions. Venous thromboembolic events (VTE) can happen without any warning signs or symptoms, and they can go untreated and unnoticed by a healthcare provider. Pain in the leg, swelling in the ankle or foot, redness or obvious discolouration areas, rapid breathing, chest pain, and other symptoms may be associated with pulmonary embolism (PE) or Bleeding and nausea are both common side effects. Bleeding around the spine and allergy reactions are also possible adverse effects. The National Institute for Health and Clinical Excellence recommends apixaban for the prevention of stroke and systemic embolism in patients who have non-valvular atrial fibrillation and at least one of the risk factors listed below: past stroke or transient ischemic attack, age 75 or older, diabetes mellitus, or symptomatic heart failure are also factors to consider. Eliquis is the brand name for the drug apixaban. Factor Xa is a trypsin-like serine protease involved in the coagulation of blood.
Global Apixaban Market Dynamics
.
Investment through government and private bodies
The market for apixaban is predicted to develop as the prevalence of venous thromboembolism-related disorders rises. Furthermore, the apixaban market is predicted to rise as the number of therapeutic indications for the drug grows. For example, the US Food and Drug Administration authorized Eliquis in 2014 for the prevention and treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE), as well as for the reduction of the risk of recurring PE and DVT after initial therapy. Furthermore, both the government and private organizations are investing heavily in healthcare research and development, which is expected to boost the Apixaban market. Adoption of apixaban is predicted to be hampered by side effects such as an increased risk of thrombotic events following premature withdrawal and bleeding. As a result, the market's growth is projected to be negatively affected.
Global Apixaban Market Segmentation
The global Apixaban {Eliquis} market is segmented based on dosage form, distribution channel, route of administration and region.
On the basis of dosage form, the global Apixaban {Eliquis} market is segmented into Tablets and Capsules. Based on distribution channel, the target market is segmented into Hospital, Retail pharmacies, Online pharmacies and Clinics. On the basis of route of administration, the target market is segmented into Oral and Injectable.
Regional Insights:
On region the global Apixaban {Eliquis} market is segmented into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. North America is expected to dominate the global Apixaban {Eliquis} market. The high prevalence of cardiovascular disorders that require anticoagulant treatment, as well as new product launches around the globe, are driving market expansion in this region. Furthermore, the rising prevalence of venous thromboembolic events has boosted apixaban's popularity in the North American market. According to a 2010 study published in the American Journal of Preventive Medicine, venous thromboembolism (VTE) affects roughly 300,000-600,000 persons in the United States each year, resulting in significant mortality. Furthermore, venous thromboembolism (VTE) problem can affect people of various races, ages, and genders. Due to increased healthcare initiatives by various governments, the Asia Pacific market is predicted to grow significantly over the forecast period, followed by the Europe market.
Report Scope:
|
Attribute |
Details |
|
Base year for estimation |
2020 |
|
Forecast period |
2020 – 2030 |
|
Market representation |
Revenue in USD Million & CAGR from 2020 – 2030 |
|
Market Segmentation |
By Dosage Form- Tablets and Capsules By Route of Administration– Hospitals & Clinics and Home Test By Distribution Channel– Oral and Injectable |
|
Regional scope |
North America - U.S., Canada Europe - UK, Germany, Spain, France, Italy, Russia, Rest of Europe Asia Pacific - Japan, India, China, South Korea, Australia, Rest of Asia-Pacific Latin America - Brazil, Mexico, Argentina, Rest of Latin America Middle East & Africa - South Africa, Saudi Arabia, UAE, Rest of Middle East & Africa |
|
Report coverage |
Revenue forecast, company share, competitive landscape, growth factors, and trends |
Segments Covered in the Report:
This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends and opportunities in each of the sub-segments from 2020 to 2030. For the purpose of this study, has segmented the global Apixaban {Eliquis} market report based on dosage form, distribution channel, route of administration and region.
Global Apixaban {Eliquis} Market, By Region:
-
-
- North America
-
- U.S.
- Canada
-
- Europe
-
- Germany
- UK
- France
- Russia
- Italy
- Rest of Europe
-
- Asia Pacific
-
- China
- India
- Japan
- South Korea
- Rest of Asia Pacific
-
- Latin America
-
- Brazil
- Mexico
- Rest of Latin America
-
- Middle East & Africa
-
- GCC
- Israel
- South Africa
- Rest of Middle East & Africa
-
- North America
-
Global Apixaban Market Key Players
The key players operating in the global Apixaban {Eliquis} market includes Abbott, Roche, Bristol-Myers Squibb, Siemens, Portola Pharmaceuticals, C. H. Boehringer Sohn, Pfizer, CoaguSense and Alere. To establish a dominant position in the market, industry players are concentrating on the development of new technologies, mergers, and collaborations. For example, in 2016, Pfizer and Bristol-Myers Squibb partnered with Portola Pharmaceuticals to commercialize and develop investigational Andexanet Alfa, a clinical phase 3 drug that is being developed to reverse the anticoagulant effect of Factor Xa inhibitors and will be beneficial to patients taking Eliquis who are experiencing major bleeding problems.
Global Apixaban Market Company Profile
- Abbott.*
- Company Overview
- Product Portfolio
- Key Highlights
- Financial Performance
- Business Strategies
- Roche
- Bristol-Myers Squibb
- Siemens
- Portola Pharmaceuticals
- C. H. Boehringer Sohn
- Pfizer
- CoaguSense
- Alere
“*” marked represents similar segmentation in other categories in the respective section
Global Apixaban Market Table of Contents
- Research Objective and Assumption
- Preface
- Research Objectives
- Study Scope
- Years Considered for the study
- Assumptions
- Abbreviations
- Research Methodology
- Research data
- Primary Data
- Primary Interviews
- Primary Breakdown
- Key data from Primary Sources
- Key Thickness Insights
- Secondary Data
- Major Secondary Sources
- Secondary Sources
- Market Estimation
- Top-Down Approach
- Approach for estimating Market Share by Top-Down Analysis (Supply Side)
- Bottom-Up Approach
- Approach for estimating market share by Bottom-up Analysis (Demand Side)
- Market Breakdown and Data Triangulation
- Research Assumptions
- Market Purview
- Executive Summary
- Key Findings—Global Outlook for Apixaban {Eliquis} Strategies
- Key Questions this Study will Answer
- Market Snippet, By Dosage form
- Market Snippet, By Distribution channel
- Market Snippet, By Route of administration
- Market Snippet, By Region
- Opportunity Map Analysis
- Executive Summary—3 Big Predictions
- Market Dynamics, Regulations, and Trends Analysis
- Market Dynamics
- Drivers
- Restraints
- Market Opportunities
- Market Trends
- DR Impact Analysis
- PEST Analysis
- Porter’s Five Forces Analysis
- Opportunity Orbit
- Market Investment Feasibility Index
- Macroeconomic Factor Analysis
- Market Dynamics
- Global Apixaban {Eliquis} Market, By Dosage form, 2020 – 2030, (US$ Mn)
- Tablets
- Market Value and Forecast (US$ Mn), and Share Analysis (%), 2020 – 2030
- Y-o-Y Growth Analysis (%), 2020 – 2030
- Segment Trends
- Capsules
- Overview
- Market Size and Forecast (US$ Mn), and Y-o-Y Growth (%), 2020 – 2030
- Tablets
- Global Apixaban {Eliquis} Market, By Distribution Channel, 2020 – 2030, (US$ Mn)
- Hospital
- Market Value and Forecast (US$ Mn), and Share Analysis (%), 2020 – 2030
- Y-o-Y Growth Analysis (%), 2020 – 2030
- Segment Trends
- Retail pharmacies
- Overview
- Market Size and Forecast (US$ Mn), and Y-o-Y Growth (%), 2020 – 2030
- Online pharmacies
- Overview
- Market Size and Forecast (US$ Mn), and Y-o-Y Growth (%), 2020 – 2030
- Clinics
- Overview
- Market Size and Forecast (US$ Mn), and Y-o-Y Growth (%), 2020 – 2030
- Hospital
- Global Apixaban {Eliquis} Market, By Route of administration, 2020 – 2030, (US$ Mn)
- Oral
- Market Value and Forecast (US$ Mn), and Share Analysis (%), 2020 – 2030
- Y-o-Y Growth Analysis (%), 2020 – 2030
- Segment Trends
- Injectable
- Overview
- Market Size and Forecast (US$ Mn), and Y-o-Y Growth (%), 2020 – 2030
- Oral
- Global Apixaban {Eliquis} Market, By Region, 2020 – 2030, (US$ Mn)
- Overview
- Market Value and Forecast (US$ Mn), and Share Analysis (%), 2020 – 2030
- Y-o-Y Growth Analysis (%), 2020 – 2030
- Regional Trends
- North America
- Market Size and Forecast (US$ Mn), By Dosage form, 2020 – 2030
- Market Size and Forecast (US$ Mn)By Distribution channel, 2020 – 2030
- Market Size and Forecast (US$ Mn), By Route of administration, 2020 – 2030
- Market Size and Forecast (US$ Mn), By Country, 2020 – 2030
- U.S.
- Canada
- Europe
- Market Size and Forecast (US$ Mn), By Dosage form, 2020 – 2030
- Market Size and Forecast (US$ Mn)By Distribution channel, 2020 – 2030
- Market Size and Forecast (US$ Mn), By Route of administration, 2020 – 2030
- Market Size and Forecast (US$ Mn), By Country, 2020 – 2030
- Germany
- UK
- France
- Russia
- Italy
- Rest of Europe
- Asia Pacific
- Market Size and Forecast (US$ Mn), By Dosage form, 2020 – 2030
- Market Size and Forecast (US$ Mn)By Distribution channel, 2020 – 2030
- Market Size and Forecast (US$ Mn), By Route of administration, 2020 – 2030
- Market Size and Forecast (US$ Mn), By Country, 2020 – 2030
- China
- India
- Japan
- South Korea
- Rest of Asia Pacific
- Latin America
- Market Size and Forecast (US$ Mn), By Dosage form, 2020 – 2030
- Market Size and Forecast (US$ Mn)By Distribution channel, 2020 – 2030
- Market Size and Forecast (US$ Mn), By Route of administration, 2020 – 2030
- Market Size and Forecast (US$ Mn), By Country, 2020 – 2030
- Brazil
- Mexico
- Rest of Latin America
- Middle East & Africa
- Market Size and Forecast (US$ Mn), By Dosage form, 2020 – 2030
- Market Size and Forecast (US$ Mn)By Distribution channel, 2020 – 2030
- Market Size and Forecast (US$ Mn), By Route of administration, 2020 – 2030
- Market Size and Forecast (US$ Mn), By Country, 2020 – 2030
- GCC
- Israel
- South Africa
- Rest of Middle East
- Overview
- Competitive Landscape
- Heat Map Analysis
- Market Presence and Specificity Analysis
- Company Profiles
- Abbott.
- Company Overview
- Product Portfolio
- Key Highlights
- Financial Performance
- Business Strategies
- Roche
- Bristol-Myers Squibb
- Siemens
- Portola Pharmaceuticals
- C. H. Boehringer Sohn
- Pfizer
- CoaguSense
- Alere
The Last Word
-
- Future Impact
- About Us
- Contact
FAQs
The global Apixaban {Eliquis} market is segmented based on dosage form, distribution channel, route of administration, and region.
The market for apixaban is predicted to develop as the prevalence of venous thromboembolism-related disorders rises
North America is expected to dominate the global Apixaban {Eliquis} market. This is mainly due to the high prevalence of cardiovascular disorders that require anticoagulant treatment, as well as new product launches around the globe, are driving market expansion in this region.
To establish a dominant position in the market, industry players are concentrating on the development of new technologies, mergers, and collaborations.